[HTML][HTML] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing …
M Campone, H Cortes-Funes, D Vorobiof… - British journal of …, 2006 - nature.com
To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
[PDF][PDF] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after …
M Campone, H Cortes-Funes, D Vorobiof… - British Journal of …, 2006 - academia.edu
Objectives This study was a multicentre, international, nonrandomised Phase II trial,
designed to determine the objective response of intravenous VFL administered once every 3 …
designed to determine the objective response of intravenous VFL administered once every 3 …
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first …
M Campone, H Cortes-Funes… - British journal of …, 2006 - pubmed.ncbi.nlm.nih.gov
To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin
targeted agent vinflunine (VFL)(320 mg m (-2) q 21 days) as second-line chemotherapy in …
targeted agent vinflunine (VFL)(320 mg m (-2) q 21 days) as second-line chemotherapy in …
[HTML][HTML] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing …
M Campone, H Cortes-Funes, D Vorobiof… - British Journal of …, 2006 - ncbi.nlm.nih.gov
To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
[引用][C] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after …
M CAMPONE, H CORTES-FUNES… - British journal of …, 2006 - pascal-francis.inist.fr
Vinflunine : a new active drug for second-line treatment of advanced breast cancer. Results
of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline …
of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline …
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first …
M Campone, H Cortes-Funes… - British Journal of …, 2006 - search.ebscohost.com
To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin
targeted agent vinflunine (VFL)(320 mg m (-2) q 21 days) as second-line chemotherapy in …
targeted agent vinflunine (VFL)(320 mg m (-2) q 21 days) as second-line chemotherapy in …
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first …
M Campone, H Cortes-Funes, D Vorobiof… - British Journal of …, 2006 - europepmc.org
To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
[PDF][PDF] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after …
M Campone, H Cortes-Funes, D Vorobiof… - British Journal of …, 2006 - Citeseer
Objectives This study was a multicentre, international, nonrandomised Phase II trial,
designed to determine the objective response of intravenous VFL administered once every 3 …
designed to determine the objective response of intravenous VFL administered once every 3 …
[PDF][PDF] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after …
M Campone, H Cortes-Funes, D Vorobiof… - British Journal of …, 2006 - researchgate.net
Objectives This study was a multicentre, international, nonrandomised Phase II trial,
designed to determine the objective response of intravenous VFL administered once every 3 …
designed to determine the objective response of intravenous VFL administered once every 3 …
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first …
M Campone, H Cortes-Funes, D Vorobiof… - British Journal of …, 2006 - europepmc.org
To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …